e-Therapeutics looks for £40m for PhII cancer trial
This article was originally published in Scrip
UK-based e-Therapeutics plans to raise £40 million through an issue of 125 million new shares in a bid to give the company enough cash to advance its cancer candidate, ETS2101 (dexanabinol) into Phase II.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.